Bandingkan Harga & Kinerja Perdana Karya Perkasa Tbk (PKPK) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Perdana Karya Perkasa Tbk dan Organon Pharma Indonesia Tbk.: Perdana Karya Perkasa Tbk diperdagangkan di Rp4.450 (kapitalisasi pasar 5,34 T, volume 24 jam 1,08 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Perdana Karya Perkasa Tbk jauh lebih besar — sekitar 51,1× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| PKPK | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 5,34 T | 104,4 M |
Volume | 1,08 jt | — |
Lot | 10,75 rb | — |
Perputaran | 4,78 M | — |
Harga Rata-rata | 4.443,43 | — |
Nilai Transaksi | 4,78 M | — |
Harga Ekuilibrium Indikatif | 4.450 | — |
Volume Ekuilibrium Indikatif | 781 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Perdana Karya Perkasa Tbk
PT Perdana Karya Perkasa (the company) was established under its original name of PT Perdana Karya Kaltim on Dec 7, 1983 then changed to PT Perdana Karya Perkasa based on Notaries Deed dated Jun 30, 2006 and the deed of establishment was approved by the the Ministry of Justice dated Aug 9, 2006. The Company articles of association has been amended several times, most recently by notarial deed No. 46 of Marina Soewana, S.H., dated Sep 28, 2006, concerning among others, the change in the Company name and public offering
Selengkapnya di halaman PKPK →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
